Treatment Strategy for Relapsed/Refractory Hodgkin Lymphoma

Patientes with Refractory/relapsed Hodgkin Lymphoma (HL R/R) with multiple failed therapies represent a therapeutic dilemma. The goal of next-line treatment is long-term disease control with manageable adverse reactions. Given the limited therapeutic options for patients with HL R/R, better therapies should be sought, more effective, with better tolerability, less toxicity, with increased overall survival (OS) of the patients, with the aim of improving outcomes in terms of disease-free survival progression (PFS) of the current standard treatment. Since currently only 50% of the patients with high-risk R/R HL treated with the standard regimen achieve healing. The high effectiveness and low toxicity of immunotherapy with prolonged remission or stabilization of the disease make it a new treatment option promising for HL R/R. Based on the above, a treatment strategy is proposed to rescue base with Brentuximab plus PD-1 blockade followed by autotransplantation and consolidation with Brentuximab plus PD-1 blockade in patients with Hodgkin lymphoma High-Risk Relapse/Refractory Compared to Reported OS and PFS Rates in the literature obtained with standard treatment.

Inclusion criteria

• Relapsed/refractory Hodgkin lymphoma to ABVD with definition of high risk.
• Age ≥ 18 years and ≤ 90 years.
• Adequate liver function, defined as:

• Total serum bilirubin ≤ 1.5 x upper limit of normal (ULN)
• Serum aspartate aminotransferase (AST) ≤ 3.0 x ULN
• Serum alanine aminotransferase (ALT) ≤ 3.0 x ULN
• Adequate renal functions, defined as:

• Serum creatinine ≤ 1.5x ULN or glomerular filtration rate > 50ml/min.
• ECOG performance status ≤ 3
• Women of reproductive potential should have a serum pregnancy test or negative urine.
• Prior signature of the informed consent.

Exclusion criteria

• Voluntary withdrawal from the study.
• Develop grade 3 or 4 toxicity according to the INH scale.
• Loss of follow-up